Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Company provides update on FDA review of Cellegesic NDA
August 4th, 2005
Cellegy Pharmaceuticals, Inc., (CLGY) announced that it has been informed by the U.S. Food and Drug Administration (FDA) that the FDA is still reviewing the company's recently submitted amended new drug application (NDA). The NDA is for Cellegesic (0.4% nitroglycerin ointment), for the treatment of pain associated with chronic anal fissure. The company expects the agency to respond soon after its review is completed. Cellegy Pharmaceuticals is a specialty-biopharmaceutical company that develops and commercializes prescription drugs for the treatment of women's healthcare conditions. This article was prepared by...
Source: Women's Health Weekly (2005-08-04)
|
